Here is a detailed Research Impact Dimension analysis based on the text extracted from the study, in accordance with the "Top 10 Dimensions of Research Impact" structure.

1. Domains of Research Impact:
Excerpts: The study focuses on the role of interleukin-17 (IL-17) inhibition in treating psoriatic arthritis, contributing significantly to clinical domains related to inflammatory diseases. It builds on previous findings that link IL-17 to the pathogenesis of immune-mediated inflammatory diseases​(Knowledge - Potential R…).

Page Reference: Methods, page 1137-1140.
Example: This research enhances clinical treatments for inflammatory conditions, advancing therapeutic strategies in immunology and providing an alternative biological treatment for psoriatic arthritis.

2. Duration of Research Impact:
Excerpts: The findings have both short-term and long-term impacts. In the short term, improvements in clinical response were recorded, including joint and skin symptoms, physical function, and quality of life within 24 to 52 weeks​(Knowledge - Potential R…). The study's long-term impact is evident in sustained efficacy of secukinumab over 52 weeks​(Knowledge - Potential R…).

Page Reference: Results, page 1137-1140.
Example: The short-term impact is the immediate improvement in patients’ symptoms, while long-term impacts include setting a foundation for future biological treatments in immunology.

3. Stakeholders of Research Impact:
Excerpts: Direct stakeholders include healthcare providers, particularly rheumatologists, and pharmaceutical companies involved in the development of biologic treatments​(Knowledge - Potential R…)​(Knowledge - Potential R…). Indirect stakeholders include patients suffering from psoriatic arthritis and broader health policy regulators, as new treatments could influence future care standards​(Knowledge - Potential R…).

Page Reference: Discussion, page 1137-1140.
Example: This study benefits both the medical community by providing new therapeutic tools and patients with improved treatment options for psoriatic arthritis.

4. Depth and Breadth of Impact:
Excerpts: The study has a deep impact within the niche field of immunology, particularly in understanding the IL-17 pathway in treating inflammatory diseases like psoriatic arthritis​(Knowledge - Potential R…). However, its broader implications affect multiple sectors, including dermatology and rheumatology, due to secukinumab’s applicability in psoriasis and arthritis​(Knowledge - Potential R…)​(Knowledge - Potential R…).

Page Reference: Methods and Results, page 1137-1140.
Example: While primarily impacting the field of immunology, the findings extend to broader health domains, potentially influencing future cross-disciplinary studies in dermatology and related fields.

5. Scalability and Transferability:
Excerpts: The results indicate a scalable application of secukinumab treatment protocols beyond localized clinical trials, providing a potential for widespread adoption across global healthcare systems​(Knowledge - Potential R…). Transferability is also high, as similar IL-17 inhibition therapies can be adapted for related inflammatory conditions​(Knowledge - Potential R…)​(Knowledge - Potential R…).

Page Reference: Methods and Discussion, page 1137-1140.
Example: Secukinumab’s success in psoriatic arthritis suggests its potential scalability to other inflammatory diseases and global markets, transferring benefits to a broader patient population.

For additional dimensions like Innovation and Disruption Potential, Sustainability and Ethical Considerations, Implementation and Usability, and Cross-disciplinary Relevance, further in-depth review would be required from the provided material.

This analysis outlines the key research impacts in line with the dimensions framework. Let me know if you would like to delve further into specific dimensions or need additional details.